MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
MYBL2
bioinformatics
prognosis
prostate cancer
tumor immune microenvironment
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
12
2021
accepted:
17
02
2022
entrez:
22
3
2022
pubmed:
23
3
2022
medline:
23
3
2022
Statut:
epublish
Résumé
MYB proto-oncogene like 2 (MYBL2) is a member of the MYB family of transcription factor genes and overexpressed in many cancers. We investigated the role of MYBL2 in the malignant progression of prostate cancer (PCa) and its relationship with immune infiltrates in PCa. Gene expression level, clinicopathological parameters, Gene Ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway, tumor immune infiltration analysis were based on The Cancer Genome Atlas (TCGA) dataset. Gene set enrichment analysis (GSEA) and single-sample gene set enrichment analysis (ssGSEA) were conducted to analyze the correlation between MYBL2 and immune infiltrates. The data processing analysis based on R language. The relationship between MYBL2 expression and immune response in PCa was analyzed on TIMER 2.0. MYBL2 was overexpressed in PCa patients, and correlated with T-stage, Gleason score, primary therapy outcome and progress free interval (PFI) event. The multivariate Cox regression analysis revealed MYBL2 was an independent risk factor for PFI (HR=1.250, 95% CI=1.016-1.537, p=0.035). The receiver operating characteristic (ROC) curve for MYBL2 (AUC=0.887) and nomogram also confirmed the diagnostic value of MYBL2 in the treatment of PCa patients. Based on mRNA expression of MYBL2, PCa patients were divided into MYBL2-high group and MYBL2-low group, and analysis of MYBL2 associated KEGG and GO pathways using R language revealed that 6 immune-related signaling pathways were enriched in MYBL2-high expression phenotype. GSEA analysis showed that 3 hallmark gene sets related to immune response were significantly enriched in MYBL2-high group, ssGSEA analysis found that MYBL2 expression correlated with the expression of many tumor immune lymphocytes (CD8+T cells, neutrophil cells, macrophage cells and so on) and immune check point inhibitors (CD276, BTLA, TNFRSF18, HAVCR2 and CD70). MYBL2 is a novel independent prognostic biomarker and MYBL2 may play a crucial role in tumor immune microenvironment of PCa.
Identifiants
pubmed: 35313552
doi: 10.2147/IJGM.S351638
pii: 351638
pmc: PMC8934167
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3003-3030Informations de copyright
© 2022 Jiao et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
EMBO J. 1994 Dec 15;13(24):5994-6005
pubmed: 7813437
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Prostate. 2020 Jun;80(9):674-686
pubmed: 32294305
Theranostics. 2021 Mar 31;11(12):5794-5812
pubmed: 33897882
J Natl Compr Canc Netw. 2020 Apr;18(4):479-489
pubmed: 32259782
Cancer Res. 2011 Aug 15;71(16):5370-3
pubmed: 21828240
Cell Death Dis. 2017 Jun 22;8(6):e2895
pubmed: 28640249
CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e79
pubmed: 24132163
Nat Rev Cancer. 2012 Mar 01;12(4):289-97
pubmed: 22378189
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Lancet Oncol. 2021 Nov;22(11):1618-1631
pubmed: 34678156
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Cancer Treat Rev. 2020 Aug;88:102030
pubmed: 32505807
Cancer Res. 2002 Dec 1;62(23):6803-7
pubmed: 12460888
Eur Urol. 2022 Feb;81(2):216-218
pubmed: 34895922
Chin Clin Oncol. 2019 Oct;8(S1):S13
pubmed: 31684733
Cell Cycle. 2021 Nov;20(21):2291-2308
pubmed: 34585645
Expert Rev Anticancer Ther. 2020 Dec;20(12):1107-1119
pubmed: 33073649
Cell Mol Life Sci. 2003 Nov;60(11):2389-401
pubmed: 14625684
Oncogenesis. 2021 Feb 26;10(2):19
pubmed: 33637673
Cancer Lett. 2022 Jan 28;525:9-21
pubmed: 34715253
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Curr Treat Options Oncol. 2020 Feb 11;21(3):21
pubmed: 32048071
Urol Oncol. 2016 Apr;34(4):182-92
pubmed: 24495446
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Transl Androl Urol. 2015 Jun;4(3):365-80
pubmed: 26814148
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Cancer Res. 2020 Apr 15;80(8):1615-1623
pubmed: 32066566
Eur Rev Med Pharmacol Sci. 2008 May-Jun;12(3):167-75
pubmed: 18700688
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):126-136
pubmed: 29556048
Histopathology. 2017 Nov;71(5):823-834
pubmed: 28594149
Sci Rep. 2022 Jan 20;12(1):816
pubmed: 35058484
BJU Int. 2012 Jul;110(2 Pt 2):E99-104
pubmed: 22177289
Cancer Lett. 2020 Feb 1;470:8-17
pubmed: 31811905
Stem Cells. 2008 Jan;26(1):173-81
pubmed: 17901403
Oncogene. 1999 Oct 14;18(42):5821-30
pubmed: 10523863